Literature DB >> 12039794

Glycogen synthase kinase-3beta: a novel regulator of cardiac hypertrophy and development.

Stefan E Hardt1, Junichi Sadoshima.   

Abstract

Glycogen synthase kinase-3beta (GSK-3beta) is a ubiquitously expressed constitutively active serine/threonine kinase that phosphorylates cellular substrates and thereby regulates a wide variety of cellular functions, including development, metabolism, gene transcription, protein translation, cytoskeletal organization, cell cycle regulation, and apoptosis. The activity of GSK-3beta is negatively regulated by protein kinase B/Akt and by the Wnt signaling pathway. Increasing lines of evidence show that GSK-3beta is an essential negative regulator of cardiac hypertrophy and that the inhibition of GSK-3beta by hypertrophic stimuli is an important mechanism contributing to the development of cardiac hypertrophy. GSK-3beta also plays an important role in regulating cardiac development. In this review, the role of GSK-3beta in cardiac hypertrophy and development and the potential underlying mechanisms are discussed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12039794     DOI: 10.1161/01.res.0000018952.70505.f1

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  112 in total

1.  MMFPh: a maximal motif finder for phosphoproteomics datasets.

Authors:  Tuobin Wang; Arminja N Kettenbach; Scott A Gerber; Chris Bailey-Kellogg
Journal:  Bioinformatics       Date:  2012-04-23       Impact factor: 6.937

2.  Dysfunctional ryanodine receptor and cardiac hypertrophy: role of signaling molecules.

Authors:  Naohiro Yamaguchi; Asima Chakraborty; Daniel A Pasek; Jeffery D Molkentin; Gerhard Meissner
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-03-18       Impact factor: 4.733

3.  miR-9 and NFATc3 regulate myocardin in cardiac hypertrophy.

Authors:  Kun Wang; Bo Long; Jing Zhou; Pei-Feng Li
Journal:  J Biol Chem       Date:  2010-02-21       Impact factor: 5.157

4.  Glycogen synthase kinase (GSK)-3 promotes p70 ribosomal protein S6 kinase (p70S6K) activity and cell proliferation.

Authors:  Sejeong Shin; Laura Wolgamott; Yonghao Yu; John Blenis; Sang-Oh Yoon
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-07       Impact factor: 11.205

Review 5.  GSK3beta: role in therapeutic landscape and development of modulators.

Authors:  S Phukan; V S Babu; A Kannoji; R Hariharan; V N Balaji
Journal:  Br J Pharmacol       Date:  2010-03-19       Impact factor: 8.739

Review 6.  Winding through the WNT pathway during cellular development and demise.

Authors:  F Li; Z Z Chong; K Maiese
Journal:  Histol Histopathol       Date:  2006-01       Impact factor: 2.303

Review 7.  Signaling mechanisms in neuroendocrine tumors as targets for therapy.

Authors:  Barbara Zarebczan; Herbert Chen
Journal:  Endocrinol Metab Clin North Am       Date:  2010-12       Impact factor: 4.741

Review 8.  Mechanical stress-strain sensors embedded in cardiac cytoskeleton: Z disk, titin, and associated structures.

Authors:  Masahiko Hoshijima
Journal:  Am J Physiol Heart Circ Physiol       Date:  2006-04       Impact factor: 4.733

9.  2,5-Dimethylcelecoxib prevents pressure-induced left ventricular remodeling through GSK-3 activation.

Authors:  Ai Fujita; Fumi Takahashi-Yanaga; Sachio Morimoto; Tatsuya Yoshihara; Masaki Arioka; Kazunobu Igawa; Katsuhiko Tomooka; Sumio Hoka; Toshiyuki Sasaguri
Journal:  Hypertens Res       Date:  2016-09-15       Impact factor: 3.872

Review 10.  Glycogen synthase kinase 3 (GSK3) in the heart: a point of integration in hypertrophic signalling and a therapeutic target? A critical analysis.

Authors:  P H Sugden; S J Fuller; S C Weiss; A Clerk
Journal:  Br J Pharmacol       Date:  2008-01-21       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.